NAKAMURA & PARTNERS
アクセス
  • MESSAGE
  • 事務所紹介
  • 業務内容
  • 弁護士・弁理士
  • 執筆・講演情報
  • 法情報提供
  • 採用情報
  • ご挨拶
  • 事務所紹介
  • 業務内容
  • 弁護士・弁理士
  • 執筆・講演情報
  • 法情報提供
  • 採用情報

法情報提供

  • 全カテゴリ
  • 特許
  • 特許 (Links)
  • 商標
  • 商標 (Links)
  • 意匠
  • 意匠 (Links)
  • 著作権
  • 著作権 (Links)
  • 知財一般
  • 知財一般 (Links)
  • 法律
  • 法律 (Links)
■

2019(Gyo-Ke)10118 (June 17, 2020) “TOPICAL OPHTHALMIC FORMULATIONS CONTAINING DOXEPIN DERIVATIVES FOR TREATING ALLERGIC EYE DISEASES” Case

January 28,2022

Inventive step and “effect”

After Supreme Court case 2018(Gyo-Hi)69

(Conclusion)
Inventive step is found based on “effect”.

Even if the construction of the present unventuin is easily conceivable, inventive step was recognized as having a remarkable effect which cannot be predicted by a person skilled in the art.

⇒ “Effectiveness” is positioned as an “Independent Requirement” for inventive step.

The Previous Lawsuit Judgment did not determine to the extent of whether or not each of the Present Inventions has such an unpredictable and remarkable effect; and therefore, it is construed that the binding effect of the Previous Lawsuit Judgment (Article 33, paragraph (1) of the Administrative Case Litigation Act) does not extend to this issue.

<Writer: Hideki Takaishi (Attorney-at-law licensed in Japan and California)>

https://www.ip.courts.go.jp/app/files/hanrei_en/741/002741.pdf

 

 
<< Prev    Next >>

  • サイトマップ
  • 利用規約
  • 免責事項
  • 個人情報保護方針
  • 事業主行動計画

Copyright © 2023 Nakamura & Partners All Rights Reserved.

  1. サイトマップ
  2. 利用規約
  3. 免責事項
  1. 個人情報保護方針
  2. 事業主行動計画

Copyright © 2023 Nakamura & Partners All Rights Reserved.